| Literature DB >> 17117591 |
Mohamed M Thabet1, Tom W J Huizinga.
Abstract
Wyeth Research was developing apratastat (TMI-005), one in a series of dual TNFalpha-converting enzyme and matrix metalloprotease-13 inhibitors, for the potential treatment of inflammation, especially rheumatoid arthritis. By January 2005, apratastat had entered a phase II clinical trial; however, in October 2006, Wyeth reported that it had terminated development of the drug because of lack of efficacy in this trial.Entities:
Mesh：
Substances：
Year: 2006 PMID： 17117591
Source DB: PubMed Journal: Curr Opin Investig Drugs ISSN： 1472-4472